Trial finds adding immunotherapy to neoadjuvant chemoradiation may improve outcomes in esophageal cancer

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made tumors more amenable to surgery, which was associated with significantly improved outcomes.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup